Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

被引：368

作者：

Andes, David ^{[1
]}

Pascual, Andres ^{[2
,3
]}

Marchetti, Oscar ^{[2
,3
]}

机构：

[1] Univ Wisconsin, Sect Infect Dis & Med Microbiol & Immunol, Dept Med, Madison, WI 53792 USA

[2] CHU Vaudois, Dept Med, CH-1011 Lausanne, Switzerland

[3] Univ Lausanne, CH-1011 Lausanne, Switzerland

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2009年 / 53卷 / 01期

关键词：

LIPOSOMAL AMPHOTERICIN-B; PERFORMANCE LIQUID-CHROMATOGRAPHY; MULTIPLE-DOSE PHARMACOKINETICS; ORAL SOLUTION; POPULATION PHARMACOKINETICS; INVASIVE ASPERGILLOSIS; ITRACONAZOLE THERAPY; ADVERSE EVENTS; PLASMA-LEVELS; VORICONAZOLE;

D O I：

10.1128/AAC.00705-08

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：24 / 34

页数：11

共 103 条

[1] In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model [J].

Andes, D. ;

Diekema, D. J. ;

Pfaller, M. A. ;

Prince, R. A. ;

Marchillo, K. ;

Ashbeck, J. ;

Hou, J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) :539-550

[2] Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].

Andes, D ;

van Ogtrop, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120

[3] In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model [J].

Andes, D ;

van Ogtrop, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :938-942

[4] In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3165-3169

[5] Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].

Andes, D ;

Marchillo, K ;

Conklin, R ;

Krishna, G ;

Ezzet, F ;

Cacciapuoti, A ;

Loebenberg, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142

[6] Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model [J].

Andes, D ;

Stamsted, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :922-926

[7]

[Anonymous], J INFECT

[8] Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers [J].

Barone, JA ;

Moskovitz, BL ;

Guarnieri, J ;

Hassell, AE ;

Colaizzi, JL ;

Bierman, RH ;

Jessen, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1862-1865

[9] Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans [J].

Bekersky, I ;

Fielding, RM ;

Dressler, DE ;

Lee, JW ;

Buell, DN ;

Walsh, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :828-833

[10] COMPARISON OF AMPHOTERICIN-B ALONE AND COMBINED WITH FLUCYTOSINE IN THE TREATMENT OF CRYPTOCCAL MENINGITIS [J].

BENNETT, JE ;

DISMUKES, WE ;

DUMA, RJ ;

MEDOFF, G ;

SANDE, MA ;

GALLIS, H ;

LEONARD, J ;

FIELDS, BT ;

BRADSHAW, M ;

HAYWOOD, H ;

MCGEE, ZA ;

CATE, TR ;

COBBS, CG ;

WARNER, JF ;

ALLING, DW .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (03) :126-131

← 1 2 3 4 5 6 7 8 9 10 →